AmoyDx(300685)2023-04-14 16:00Financial Performance - The company's operating revenue for 2022 was ¥842,180,427.77, a decrease of 8.16% compared to ¥917,033,391.28 in 2021[23] - The net profit attributable to shareholders for 2022 was ¥263,743,023.32, an increase of 10.09% from ¥239,573,622.91 in 2021[23] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥156,986,572.23, a decrease of 27.21% compared to ¥215,656,757.15 in 2021[23] - The basic earnings per share for 2022 was ¥0.67, compared to ¥1.09 in 2021, reflecting a decrease of 38.5%[23] - The total assets at the end of 2022 amounted to ¥1,650,924,910.62, an increase of 8.62% from ¥1,519,881,333.25 at the end of 2021[23] - The net assets attributable to shareholders at the end of 2022 were ¥1,499,727,525.25, a rise of 9.90% from ¥1,364,580,687.78 at the end of 2021[23] - The net cash flow from operating activities for 2022 was ¥149,036,792.06, down 11.37% from ¥168,161,324.14 in 2021[23] - The weighted average return on net assets for 2022 was 18.42%, a decrease of 0.77% from 19.19% in 2021[23] Market and Product Development - The company has received approval for 24 types of single-gene and multi-gene tumor testing products, making it a leading enterprise in the industry with the most comprehensive product offerings[34] - The company has applied for over 60 invention patents, with 49 patents granted, highlighting its commitment to innovation and technology development[35] - The company is focusing on precision diagnostics in oncology, which is expected to see increased demand due to rising cancer rates and an aging population[33] - The company has developed a comprehensive companion diagnostic product system that covers targeted therapy and immunotherapy, enhancing its market position[34] - The company is actively pursuing market expansion and product innovation, with several products already approved for reimbursement in local healthcare systems[35] - The company has developed a rich line of LDT products in accordance with Class III IVD product development standards, including HRR and HRD products for guiding cancer treatments[36] - The company has established partnerships with major pharmaceutical companies for companion diagnostics, enhancing clinical trial success rates[52] Research and Development - The company has invested significantly in R&D, developing advanced technologies and holding multiple patents in precision oncology diagnostics[58] - The company invested CNY 174.53 million in R&D, representing a year-on-year increase of 11.79% and accounting for 20.72% of total revenue[62] - The company’s R&D team consists of 465 professionals, ensuring a multidisciplinary approach to innovation[63] - The company has a structured approach to governance, ensuring that compensation aligns with performance metrics and industry standards[150] Regulatory and Compliance - The company emphasizes innovation and compliance, aligning with regulatory requirements and industry trends to meet clinical demands for accurate and rapid diagnostics[37] - The company has received regulatory approval for multiple companion diagnostic products, including ROS1 and PCR-11, which are also covered by local health insurance in Japan[40] - The company has successfully completed the renewal of registration for several Class III medical devices, ensuring compliance with regulatory standards[44] - The company has obtained registration for 68 in vitro diagnostic reagent products classified as Class I[47] - The company has established a governance structure that complies with relevant laws and regulations, ensuring transparency and fairness in shareholder meetings[118] Corporate Governance - The company maintains independence from its controlling shareholder, ensuring no interference in its operational decisions[119] - The board of directors consists of 9 members, including 3 independent directors, complying with legal and regulatory requirements[120] - The company has established a performance evaluation and incentive system for senior management, ensuring transparency and compliance with laws and regulations[123] - The company emphasizes investor relations management, ensuring transparent communication with shareholders through various channels[124] Social Responsibility and Community Engagement - The company has conducted a public health project, providing free low-dose spiral CT lung cancer screenings for over 3,000 high-risk patients[182] - The company has actively participated in social responsibility initiatives, aligning economic benefits with social and environmental goals[180] - The company emphasizes teamwork and collaboration, aiming for mutual benefits among society, customers, employees, and shareholders[183] Financial Management - The company has a cash dividend policy that aligns with its articles of association, with a cash dividend of 1.4 yuan per 10 shares (including tax) proposed for distribution[166] - The total cash dividend amount (including other methods) is 155,169,115.64 yuan, which accounts for 100% of the total profit distribution[166] - The company has a significant increase in government subsidies, contributing ¥20,075,855.92, or 7.02% of total profit[93] Internal Controls - The company maintained effective internal controls with no significant defects identified in financial and non-financial reporting during the reporting period[175] - The internal control evaluation report indicated that 100% of the total assets and operating income of the evaluated units were included in the company's consolidated financial statements[175] - The company plans to continuously update its internal control measures in line with business expansion to enhance employee awareness of internal controls[173]